Wave Life Sciences Ltd (WVE) News

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy

Designation highlights significant unmet needs in DMD; dystrophin data from potentially registrational...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Successful clinical translation of Wave’s RNA medicines platform in HD patients with WVE-003 provides further...

Wave Life Sciences Second Quarter 2024 Financial Results Scheduled for August 8, 2024

CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage...

Form 4 - Statement of changes in beneficial ownership of securities

Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease

Statistically significant, potent, and durable allele-selective silencing: 46% mean reduction in CSF mutant...

Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing

Presentation at the Obesity & Weight Loss Drug Development Summit to review Real World Evidence for the...